文献速递分子诊断临床微生物

提升H5N1诊断准备:H5单重检测方法的验证及多平台检测评估

Enhancing diagnostic preparedness for H5N1: a validation study of H5 single-plex assay and detection across multiple platforms.
PubMed 文献 · J Clin Microbiol · 2025-07-18

研究评估三种商用分子诊断试剂盒对H5N1的检测限,并开发H5单重实时RT-PCR用于流感A阳性标本的反射检测。三种商用试剂盒均能在低病毒浓度下可靠检出H5N1,但缺乏H5亚型区分能力;整合H5特异性检测可减少漏诊并支持临床决策与公共卫生监测。

要点

  • 三种商用分子试剂盒均能在低病毒浓度下可靠检出H5N1。
  • 商用试剂盒无法区分流感A H5亚型。
  • 开发并验证了H5单重实时RT-PCR用于反射检测。

核心结论

  • 当前商用试剂盒缺乏流感A H5亚型区分能力,但验证数据提供关键性能信息,整合H5靶向检测可增强临床决策与公共卫生监测。

研究设计与样本

  • 评估三种商用分子诊断试剂盒(bioMérieux BioFire Respiratory 2.1 Panel、Cepheid Xpert Xpress CoV-2/Flu/RSV Plus、Hologic Panther Fusion SARS-CoV-2/Flu A/B/RSV)对H5N1的检测限。
  • 开发H5单重实时RT-PCR并在Hologic Panther Fusion Open Access平台上用于流感A阳性标本的反射检测。

主要发现

  • 三种商用试剂盒均能在低病毒浓度下可靠检出H5N1。
  • 商用多重呼吸道试剂盒可检出H5N1但缺乏H5亚型分型能力。

临床怎么用

  • 对流感A阳性标本使用H5单重实时RT-PCR进行反射检测以确认H5N1。
  • 结合商用试剂盒与H5靶向检测提升H5N1早期检出与公共卫生响应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increasing transmission of highly pathogenic avian influenza (HPAI) H5N1 from animals to humans underscores the urgent need for enhanced diagnostic capabilities in clinical microbiology laboratories. Although in silico analysis suggests that commercial multiplex respiratory panels can detect H5N1, these assays lack subtyping H5N1 capabilities, and their real-world performance remains largely unverified. In this study, we evaluated the limit of detection (LoD) for H5N1 using three commercial molecular diagnostic assays routinely employed at our institution: bioMérieux BioFire Respiratory 2.1 Panel, Cepheid Xpert Xpress CoV-2/Flu/RSV Plus, and Hologic Panther Fusion SARS-CoV-2/Flu A/B/RSV assays. All three reliably detected H5N1 were at low viral concentrations. To enable H5N1 detection, we also developed a real-time RT-PCR H5 single-plex assay on the Hologic Panther Fusion Open Access platform for reflex testing of influenza A-positive specimens. In conclusion, although current commercial assays lack influenza A H5 subtype differentiation, our validation data provide critical performance information. When integrated with a targeted H5 assay, these tools can enhance clinical decision-making and public health surveillance by reducing the risk of missed H5N1 infection cases.IMPORTANCEThis study addresses a growing public health concern: the spread of bird flu (H5N1) from animals to humans. Most hospital laboratories use commercial tests to detect respiratory viruses like the flu, but these tests cannot tell if someone has the specific and more dangerous H5N1 strain. To help solve this, we tested three commonly used diagnostic tools and found that they can detect H5N1 even at low levels. However, since they cannot identify the specific H5 subtype, we also developed and validated a follow-up test that runs on one of the existing laboratory high-throughput equipment. This test can confirm whether a patient infected with the flu has the H5N1 strain. By combining these tools, hospital laboratories can improve early detection of H5N1, support better patient care, and help public health officials respond more effectively to outbreaks.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Xue YC, Bertsch J, Monacy K, et al. Enhancing diagnostic preparedness for H5N1: a validation study of H5 single-plex assay and detection across multiple platforms. J Clin Microbiol. 2025. PMID: 40679852. doi:10.1128/jcm.00681-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。